Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1919 1
1925 1
1928 1
1946 2
1947 1
1948 1
1949 2
1951 1
1952 1
1953 2
1954 4
1955 1
1956 3
1957 4
1958 1
1959 2
1960 1
1961 6
1962 1
1963 6
1964 7
1965 5
1966 10
1967 7
1968 19
1969 14
1970 17
1971 22
1972 24
1973 18
1974 32
1975 103
1976 125
1977 114
1978 108
1979 135
1980 137
1981 135
1982 146
1983 189
1984 202
1985 258
1986 246
1987 329
1988 494
1989 595
1990 620
1991 662
1992 733
1993 793
1994 864
1995 929
1996 1102
1997 1168
1998 1244
1999 1373
2000 1567
2001 1635
2002 1634
2003 2027
2004 2378
2005 2654
2006 2888
2007 3162
2008 3451
2009 3766
2010 4162
2011 4599
2012 5198
2013 5959
2014 8087
2015 9326
2016 9880
2017 10234
2018 11547
2019 12311
2020 13146
2021 13029
2022 11717
2023 10740
2024 4845

Text availability

Article attribute

Article type

Publication date

Search Results

153,077 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.
Wang H, Cordiner RLM, Huang Y, Donnelly L, Hapca S, Collier A, McKnight J, Kennon B, Gibb F, McKeigue P, Wild SH, Colhoun H, Chalmers J, Petrie J, Sattar N, MacDonald T, McCrimmon RJ, Morales DR, Pearson ER; Scottish Diabetes Research Network Epidemiology Group. Wang H, et al. Diabetes Care. 2023 May 1;46(5):967-977. doi: 10.2337/dc22-1238. Diabetes Care. 2023. PMID: 36944118 Free PMC article. Clinical Trial.
RESEARCH DESIGN AND METHODS: A cohort study was performed including people with type 2 diabetes diagnosed in Scotland before 31 December 2017, who failed to reach HbA1c 48 mmol/mol despite metformin monotherapy and initiated second-line pharmacotherapy (SU/DPP4i/TZD …
RESEARCH DESIGN AND METHODS: A cohort study was performed including people with type 2 diabetes diagnosed in Scotland before 31 December 201 …
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Su GL, Altayar O, O'Shea R, Shah R, Estfan B, Wenzell C, Sultan S, Falck-Ytter Y. Su GL, et al. Gastroenterology. 2022 Mar;162(3):920-934. doi: 10.1053/j.gastro.2021.12.276. Gastroenterology. 2022. PMID: 35210014
RESULTS: The Panel reviewed the evidence, summarized in the Technical Review, for the following medications approved by the US Food and Drug Administration for HCC: first-line therapies: bevacizumab+atezolizumab, sorafenib, and lenvatinib; second-line therapies: cab …
RESULTS: The Panel reviewed the evidence, summarized in the Technical Review, for the following medications approved by the US Food and Drug …
Standard urotherapy as first-line intervention for daytime incontinence: a meta-analysis.
Schäfer SK, Niemczyk J, von Gontard A, Pospeschill M, Becker N, Equit M. Schäfer SK, et al. Eur Child Adolesc Psychiatry. 2018 Aug;27(8):949-964. doi: 10.1007/s00787-017-1051-6. Epub 2017 Sep 25. Eur Child Adolesc Psychiatry. 2018. PMID: 28948380 Review.
According to the International Children's Continence Society (ICCS) guidelines for the treatment of daytime urinary incontinence (DUI) in children and adolescents, the first-line intervention for all types of DUI is standard urotherapy (SU). ...Of 100 patients in 1 …
According to the International Children's Continence Society (ICCS) guidelines for the treatment of daytime urinary incontinence (DUI) in ch …
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.
Zhu J, Zhou Y, Li Q, Wang G. Zhu J, et al. Adv Ther. 2023 Oct;40(10):4216-4235. doi: 10.1007/s12325-023-02612-z. Epub 2023 Jul 29. Adv Ther. 2023. PMID: 37515713 Free PMC article. Review.
Four studies consistently discovered that SGLT2i was more cost-effective than GLP-1RA in T2D who were not adequately controlled by metformin monotherapy. Four studies compared GLP-1RA with DPP-4i, sufonylurea (SU), or insulin. Except for one that demonstrated SU was …
Four studies consistently discovered that SGLT2i was more cost-effective than GLP-1RA in T2D who were not adequately controlled by metformin …
Black Line Sign in Focal Cortical Dysplasia IIB: A 7T MRI and Electroclinicopathologic Study.
Tang Y, Blümcke I, Su TY, Choi JY, Krishnan B, Murakami H, Alexopoulos AV, Najm IM, Jones SE, Wang ZI. Tang Y, et al. Neurology. 2022 Aug 9;99(6):e616-e626. doi: 10.1212/WNL.0000000000200702. Epub 2022 May 16. Neurology. 2022. PMID: 35940890 Free PMC article.
Well-matched histopathologic slices in one case revealed accumulated dysmorphic neurons and balloon cells in the black line region. DISCUSSION: The black line sign may serve as a noninvasive marker for FCD IIB. Both MRI-pathology and qMRI analyses suggest that the b …
Well-matched histopathologic slices in one case revealed accumulated dysmorphic neurons and balloon cells in the black line region. D …
Choosing a gliptin.
Gupta V, Kalra S. Gupta V, et al. Indian J Endocrinol Metab. 2011 Oct;15(4):298-308. doi: 10.4103/2230-8210.85583. Indian J Endocrinol Metab. 2011. PMID: 22029001 Free PMC article.
The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. ...
The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-di …
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, Rini BI, Szczylik C, Choueiri TK, Heng DY. Ruiz-Morales JM, et al. Eur J Cancer. 2016 Sep;65:102-8. doi: 10.1016/j.ejca.2016.06.016. Epub 2016 Jul 31. Eur J Cancer. 2016. PMID: 27487293
BACKGROUND: Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). ...CONCLUSIONS: We confirmed in real-world practice that SU and PZ have similar efficacy in the first-line setting f …
BACKGROUND: Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinom …
Fast non-line-of-sight imaging based on product-convolution expansions.
Xu W, Chen S, Tian Y, Wang D, Su X. Xu W, et al. Opt Lett. 2022 Sep 15;47(18):4680-4683. doi: 10.1364/OL.469719. Opt Lett. 2022. PMID: 36107062
Non-line-of-sight (NLoS) imaging reveals a hidden scene using indirect diffuse reflections. ...
Non-line-of-sight (NLoS) imaging reveals a hidden scene using indirect diffuse reflections. ...
153,077 results
You have reached the last available page of results. Please see the User Guide for more information.